COWLING; BELINDA
Patent Applications and Registrations
Patent applications and USPTO patent grants for COWLING; BELINDA.The latest application filed is for "dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy".
- COWLING; BELINDA - KALTENHOUSE FR
| Patent | Date |
|---|---|
| Dynamin 2 Inhibitor For The Treatment Of Duchenne's Muscular Dystrophy App 20210130447 - LAPORTE; JOCELYN ; et al. | 2021-05-06 |
| Compositions And Method For The Treatment Of X-linked Centronuclear Myopathy App 20200405804 - LAPORTE; JOCELYN ; et al. | 2020-12-31 |
| Dynamin 2 inhibitor for the treatment of Duchenne's muscular dystrophy Grant 10,822,400 - Laporte , et al. November 3, 2 | 2020-11-03 |
| Dynamin 2 Inhibitor For The Treatment Of Centronuclear Myopathies App 20200308589 - LAPORTE; JOCELYN ; et al. | 2020-10-01 |
| Mtmr2-s Polypeptide For Use In The Treatment Of Myopathies App 20200215168 - LAPORTE; JOCELYN ; et al. | 2020-07-09 |
| Dynamin 2 inhibitor for the treatment of centronuclear myopathies Grant 10,647,986 - Laporte , et al. | 2020-05-12 |
| Dynamin 2 Inhibitor For The Treatment Of Duchenne's Muscular Dystrophy App 20180142008 - LAPORTE; JOCELYN ; et al. | 2018-05-24 |
| Dynamin 2 Inhibitor For The Treatment Of Centronuclear Myopathies App 20160264976 - LAPORTE; JOCELYN ; et al. | 2016-09-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 